MedTrace Logo

Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

NCT06145048 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2026-05-13

Study results available
· View outcomes & findings →

Summary

This is a Phase 2, multi-center, open-label study to evaluate the safety and efficacy of VGT-309, a tumor-targeted, activatable fluorescent imaging agent, in subjects undergoing surgery for proven or suspected cancer in the lung. Approximately 100 subjects will be enrolled to ensure at least 86 subjects are evaluable with the option to expand enrollment by protocol amendment if deemed necessary by the DSC to meet primary and/or secondary objectives.

Conditions

Interventions

DRUG

VGT-309

Intravenous drug to be given over 15-20 minutes by syringe pump.

Sponsors & Collaborators

  • Vergent Bioscience, Inc.

    lead INDUSTRY

Principal Investigators

  • Curtis Scribner, MD · Vergent Bioscience

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-05
Primary Completion
2024-10-31
Completion
2025-02-20
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06145048 on ClinicalTrials.gov